Literature DB >> 30670412

In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.

Pilar Ruiz1, Manuel Causse2, Manuel Vaquero1, Manuel Casal3.   

Abstract

Tedizolid is a novel oxazolidinone with activities against Gram-positive microorganisms, including mycobacteria. We studied the in vitro activity of tedizolid against 120 Mycobacterium tuberculosis strains, including susceptible, first-line-resistant, and multidrug-resistant isolates. MIC was tested using the Bactec 960 MGIT system. MIC90 and MIC50 were 0.5 and 0.25 μg/ml, respectively, in susceptible and resistant strains. Tedizolid may be an alternative in the treatment of resistant M. tuberculosis.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosiszzm321990; resistance; tedizolid

Year:  2019        PMID： 30670412      PMCID： PMC6437524          DOI： 10.1128/AAC.01939-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Tedizolid: a new oxazolidinone antimicrobial.

Authors:  Jamie J Kisgen; Hanine Mansour; Nathan R Unger; Lindsey M Childs
Journal:  Am J Health Syst Pharm       Date:  2014-04-15       Impact factor: 2.637

2.  In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Victor M Velazquez-Moreno; Sung Hak Choi; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Renal function as a predictor of linezolid-induced thrombocytopenia.

Authors:  Kazuaki Matsumoto; Yasuo Takeda; Ayumi Takeshita; Naoko Fukunaga; Akari Shigemi; Keiko Yaji; Yoshihiro Shimodozono; Katsushi Yamada; Kazuro Ikawa; Norifumi Morikawa
Journal:  Int J Antimicrob Agents       Date:  2008-09-14       Impact factor: 5.283

5.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

6.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

Review 7.  Tedizolid (TR-701): a new oxazolidinone with enhanced potency.

Authors:  Zeina A Kanafani; G Ralph Corey
Journal:  Expert Opin Investig Drugs       Date:  2012-02-13       Impact factor: 6.206

8.  In vitro activity of tedizolid against the Mycobacterium abscessus complex.

Authors:  Fabrice Compain; Daria Soroka; Beate Heym; Jean-Louis Gaillard; Jean-Louis Herrmann; Delphine Dorchène; Michel Arthur; Vincent Dubée
Journal:  Diagn Microbiol Infect Dis       Date:  2017-11-10       Impact factor: 2.803

9.  Clinical population pharmacokinetics and toxicodynamics of linezolid.

Authors:  Lauren M Boak; Craig R Rayner; M Lindsay Grayson; David L Paterson; Denis Spelman; Sharmila Khumra; Blair Capitano; Alan Forrest; Jian Li; Roger L Nation; Jurgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 10.  Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives.

Authors:  Pradeep S Jadhavar; Maulikkumar D Vaja; Tejas M Dhameliya; Asit K Chakraborti
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530
View more
  5 in total

1.  In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.

Authors:  Huiyun Zhang; Wenya Hua; Siran Lin; Yu Zhang; Xinchang Chen; Shiyong Wang; Jiazhen Chen; Wenhong Zhang
Journal:  Infect Drug Resist       Date:  2022-08-25       Impact factor: 4.177

2.  In Silico Identification of Possible Inhibitors for Protein Kinase B (PknB) of Mycobacterium tuberculosis.

Authors:  Tatiana F Vieira; Fábio G Martins; Joel P Moreira; Tiago Barbosa; Sérgio F Sousa
Journal:  Molecules       Date:  2021-10-12       Impact factor: 4.411

Review 3.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447

4.  Fabrication and Characterization of Tedizolid Phosphate Nanocrystals for Topical Ocular Application: Improved Solubilization and In Vitro Drug Release.

Authors:  Mohd Abul Kalam; Muzaffar Iqbal; Abdullah Alshememry; Musaed Alkholief; Aws Alshamsan
Journal:  Pharmaceutics       Date:  2022-06-23       Impact factor: 6.525

Review 5.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.